Skip to content
Search AI Powered

Latest Stories

Allegations of Retaliation and Fear in NY's Cannabis Industry

Allegations of hostility and retaliation have surfaced against the Office of Cannabis Management (OCM), the regulatory body overseeing the state's legal marijuana market. Stakeholders within the industry are speaking out, accusing the OCM of using enforcement powers to silence dissent and punish those who criticize its handling of the market rollout.

Allegations of Retaliation and Fear in NY's Cannabis Industry
Allegations of Retaliation and Fear in NY's Cannabis Industry

New York's fledgling cannabis industry, born from the promise of equity and economic prosperity, finds itself embroiled in controversy. Allegations of hostility and retaliation have surfaced against the Office of Cannabis Management (OCM), the regulatory body overseeing the state's legal marijuana market. Stakeholders within the industry are speaking out, accusing the OCM of using enforcement powers to silence dissent and punish those who criticize its handling of the market rollout.

The concerns about the OCM's conduct have been brewing for over a year, but recent events have brought them to the forefront. Industry insiders, including business owners and entrepreneurs like Ruben Lindo of Blak Mar Farms, express fear of reprisal if they speak out against perceived injustices. They cite instances of selective enforcement and a culture of intimidation within the agency.


The Jenny Argie Case:
Jenny Argie, a cancer survivor and licensed cannabis processor, found herself at the center of this controversy. Despite her efforts to comply with regulations and contribute positively to the market, she faced scrutiny and retaliation after speaking out about illicit practices within the industry. Her public statements and leaks of internal conversations led to her products being recalled, raising questions about the OCM's priorities and motives.

Jenny Argie, a licensed Adult-Use Conditional Processor, files suit against NY's Office of Cannabis Management Jenny Argie, the cannabis entrepreneur at the center of a allegations against NY's Office of Cannabis Management

The OCM maintains that its actions are in line with state regulations and necessary to uphold public health and safety standards. However, critics argue that the agency's enforcement efforts appear arbitrary and disproportionate, targeting small operators like Argie while overlooking more egregious violations by larger players.

Argie's case is not an isolated incident but rather part of a pattern of alleged retaliation and intimidation by the OCM. Other industry stakeholders, including cultivators and lobbyists, have reported similar experiences of harassment and fear of retribution for speaking out against perceived injustices.

According to an article in NY Cannabis Insider, in early February, Joe Rossi, the cannabis practice group leader at lobbying and consulting firm Park Strategies –– which represents a number of cannabis businesses –– criticized the OCM on Twitter for its lag in licensing.

Fagon, the chief equity officer, took a screenshot of the tweet and posted it on his personal Instagram with the comment: “Please stop twisting yourself in knots so publicly because you don’t understand the industry.”

In a bold move, Argie has taken legal action against the OCM, challenging the agency's conduct and seeking relief from what she views as retaliatory measures. Her lawsuit shines a light on the power dynamics at play within New York's cannabis industry and raises fundamental questions about accountability and transparency.

Argie's case has sparked broader calls for accountability within the OCM and the Cannabis Control Board. Industry advocates and lawmakers are urging independent audits and investigations to ensure that regulatory agencies are fulfilling their mandates fairly and impartially.

As the legal battle between Argie and the OCM unfolds, the cannabis industry in New York stands at a crossroads. The outcome of this case could have far-reaching implications for the future of regulation and governance in the state's burgeoning market. It underscores the importance of vigilance and accountability in safeguarding the integrity of the cannabis industry and protecting the rights of all stakeholders involved.

More For You

Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Giphy

Aging & Cannabis: New Findings

For decades, cannabis has been widely regarded as a substance with potential cognitive risks, particularly when used over long periods. Governments across the globe have classified it as a controlled substance, citing concerns about the effects of marijuana use, including memory loss, diminished executive function, and long-term neurological impact. But new research is challenging this long-standing assumption, suggesting that cannabis use may not be linked to age-related cognitive decline—and might even be associated with better cognitive preservation over time.

A recent study published in PubMed (NIH, 2024) followed over 5,000 men for more than four decades to analyze the long-term cognitive effects of cannabis use. The results? Men with a history of cannabis use experienced less cognitive decline from early adulthood to late midlife compared to those who never used cannabis.

Keep ReadingShow less
Lights, Camera, Cannabis: The New Theater Experience
Cigar smoking in a bar....
Giphy

NY Movie Theaters: High on Cannabis Lounges

In the dimly lit ambiance of New York City's historic movie theaters, the scent of buttered popcorn has long been the olfactory hallmark. However, as cannabis legalization sweeps across the state, a provocative question emerges: Could the future of cinema include the aroma of cannabis alongside the traditional concessions?

The Current Landscape of Cannabis Consumption Lounges

New York State’s Clean Indoor Air Act (CIAA) casts a long shadow over this budding idea. Enacted to safeguard public health, the CIAA prohibits smoking and vaping in most indoor workplaces, encompassing bars, restaurants, and, notably, movie theaters. The act defines smoking expansively, including the burning of tobacco, cannabis, or cannabinoid-hemp products. Violations can result in fines up to $2,000 for each infraction, underscoring the state’s commitment to maintaining smoke-free public spaces.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less
80s anti-drug ad, egg cooking in frying pan, indicates your "brain on drugs"
DEA's 2025 'Anti-420 Day' Campaign: A Misguided Step Backward
Giphy

DEA's Anti-420 Fail

In a move that seems more like a relic from the “Just Say No” era than a contemporary public health initiative, the Drug Enforcement Administration (DEA) is backing an “Anti-420 Day” campaign aimed at recruiting high school and college students to produce anti-cannabis content for Instagram. This initiative, which also aims to address drug abuse among high school and college students by highlighting its impact on education and behavior, is spearheaded by the anti-cannabis nonprofit Johnny’s Ambassadors. It offers modest incentives—$25 to $50 Amazon gift cards—for videos warning peers about the purported dangers of THC use.

A Disconnect from Current Drug Policy Realities

At a time when more than 23 states have embraced full cannabis legalization and public opinion has shifted significantly in favor of reform, the DEA’s endorsement of this campaign appears tone-deaf and regressive. The agency’s attempt to “flood” social media with anti-THC messages not only disregards the evolving legal landscape but also undermines efforts toward normalization and informed discourse surrounding cannabis use. A multifaceted approach to drug abuse prevention, which includes increased resources for prevention and rehabilitation, is necessary to address the complexities of drug addiction. This contrasts sharply with the DEA's current strategies that emphasize law enforcement and interdiction over public health-focused measures.

Keep ReadingShow less
What's Going on With New York's Legal Cannabis Rollout
What's Going on With New York's Legal Cannabis Rollout

What’s Going on with New York’s Legal Cannabis Roll Out? 

The New York cannabis industry is facing a complex and challenging landscape as it transitions from a medical marijuana program to a fully legal recreational market. Despite the recent legalization of adult-use cannabis in the state, there are still many issues to be addressed, including regulatory compliance, licensing, distribution, capital and equity concerns, and of course, litigation.

Recently, several lawsuits have been filed against the New York State Cannabis Control Board (CCB) and the Office of Cannabis Management (OCM), which are the agencies responsible for overseeing the state's cannabis industry.

Keep ReadingShow less